title: Age-related changes in rat brain monoamines release: peculiarity of dopamine release.
abstract: Our aim has been to investigate the ability of the rat brain to retain its level of neurotransmitter release over life. We have investigated the neurotransmitter release from the rat brain synaptosomes prelabeled with 3H-DA, 3H-NA, or 3H-5HT, and perfused with Krebs-Ringer medium alone (basal release) or containing a high K+, calcium ionophore, tyramine or amphetamine (evoked release). Brain areas have been dissected of animals 45 days and 4, 6, and 11 months old. The results have shown a gradual reduction of the 3H-NA release evoked by a high K+ from 45 days to 6 months, which is stabilized until 11 months of age. The reduction rate has been relatively different from the brain areas investigated (36% for the frontal cortex and 26% for the hippocampus and cerebellar cortex). A similar reduction has been seen with 3H-5HT released from synaptosomes of the frontal cortex, hippocampus, and striatum. Surprisingly, the 3H-DA release that was evoked by high K+ was greater in rats 11 months old than in younger rats; this effect has been seen in synaptosomes from the caudate and the frontal cortex. The calcium ionophore A23187 has shown a releasing picture similar to a high K+. When we analyzed a nonexocitotic, but probably carrier mediated, release (evoked by tyramine or amphetamine), there was reduced release of all of the above neurotransmitters from 45 days to 11 months of age. We presume that there have been adaptive changes in neurotransmitter evoked release due to changes in Ca++ utilization, as inferred from the results from calcium ionophore experiments and carrier performance.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Experimental Medicine, University of L'Aquila, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Cerrito
authors.forename: G
authors.initials: G
authors.lastname: Aloisi
authors.forename: P
authors.initials: P
authors.lastname: Arminio
mesh_terms: D000375:Aging / Q000378:metabolism*; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D015306:Biogenic Monoamines / Q000378:metabolism*; D001923:Brain Chemistry / Q000502:physiology*; D000001:Calcimycin / Q000494:pharmacology; D002421:Caudate Nucleus / Q000187:drug effects / Q000378:metabolism; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D008297:Male; D009411:Nerve Endings / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012701:Serotonin / Q000378:metabolism; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism; D014439:Tyramine / Q000494:pharmacology
chemical_list: D015306:Biogenic Monoamines; D018377:Neurotransmitter Agents; D012701:Serotonin; D000001:Calcimycin; D000661:Amphetamine; D011188:Potassium; D004298:Dopamine; D009638:Norepinephrine; D014439:Tyramine